Translate this page into:
Review Article
doi:
10.4103/2278-330X.187593
Summary of the published Indian data on chronic myeloid leukemia
1
Department of Medical Oncology, Indraprastha Apollo Hospital, New Delhi
2
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
3
Tata Medical Center, Kolkata, West Bengal
*Corresponding author: Dr. Manish K. Singhal. singhaloncocare@yahoo.co.in
MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Abstract
Chronic myelogenous leukemia (LML) was recognized as a distinct entity in the mid-1800s. Since Nowell and Hunagerford initiated their research on CML in1960 our understanding in CML has been increasing. Imatinib became the preferred treatment from 2000 onwards as a result of its unprecedented success. The lack of structured Indian data on CML led to the formation of a CML data cansortuim which invited CML data albiet retro spartive form around the country including major cancer service providers both government and private. We provide a summary of published Indian data on CML here.
Keywords
References
- Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960;25:85-109.
- Bhutani M, Vora A, Kumar L, Kochupillai V. Lympho-hemopoietic malignancies in India. Med Oncol 2002;19:141-50.
- Aziz Z, Iqbal J, Akram M, Saeed S. Treatment of chronic myeloid leukemia in the imatinib era: Perspective from a developing country. Cancer 2007;109:1138-45.
- Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood 2007;110:2828-37.
- O′Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
- O′Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: Sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM). Blood 2008;112:76.
- Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998;352:1087-92.
- Tardieu S, Brun-Strang C, Berthaud P, Michallet M, Guilhot F, Rousselot P, et al. Management of chronic myeloid leukemia in France: A multicentered cross-sectional study on 538 patients. Pharmacoepidemiol Drug Saf 2005;14:545-53.
- Cortes JE, Richard TS, Hagop K. Chronic myelogenous leukemia. In: Padzur R, Coia LR, Hoskins WJ, Wagman LD, editors. Cancer Management: A Multidisciplinary Approach. 10 th ed. Lawrence: CMPMedica; 2007. p. 789.
- Rajappa S, Varadpande L, Paul TR, Jacob RT, Digumarti R. Report of chronic myeloid leukemia in chronic phase from Dr. Senthil Rajappa, 2002-2009. Indian J Med Paediatr Oncol 2013;34:208-10.
- Agarwal MB, Agarwal UM, Rathi SS, Masurkar S, Zaveri B. Report of chronic myeloid leukemia in chronic phase from Ashirwad Hematology Centre, Mumbai, 2002-2009. Indian J Med Paediatr Oncol 2013;34:199-203.
- Bhutani M, Kochupillai V. Hematological malignancies in India. In: Kumar L, editor. Progress in Hematologic Oncology. New York: Pub. The Advanced Research Foundation New York; 2003. p. 10.
- Prasad RR, Singh P. Report of chronic myeloid leukemia from Indira Gandhi Institute of Medical Sciences, Regional Cancer Center, 2002-2009. Indian J Med Paediatr Oncol 2013;34:172-4.
- Shah SA. The treatment of chronic myeloid leukemia, data from Gujarat Cancer and Research Institute, Ahmedabad. Indian J Med Paediatr Oncol 2013;34:189-92.
- Parikh P. Report of chronic myeloid leukemia in chronic phase from Tata Memorial Hospital, Mumbai, 2002-2008. Indian J Med Paediatr Oncol 2013;34:164-7.
- Deotare UR, Chudgar U, Bhagat E. Report of patients with chronic myeloid leukemia, from hematology clinic, Ahmedabad, Gujarat 2000-2010 at 1st myelostone meeting: Indian evidence of chronic myelogenous leukemia. Indian J Med Paediatr Oncol 2013;34:193-5.
- Srinivas KG, Patil S, Shashidhara. Epidemiological and clinical profile of patients with chronic myeloid leukemia at Health-Care Global, Bangalore Institute of Oncology. Indian J Med Paediatr Oncol 2013;34:211-2.
- Ray SS, Chakraborty P, Chaudhuri U, Ganesh. Report of chronic myeloid leukemia in chronic phase from Eastern India, Institute of Hematology and Transfusion Medicine, Kolkata, 2001-2009. Indian J Med Paediatr Oncol 2013;34:175-6.
- Mishra P, Seth T, Mahapatra M, Saxena R. Report of chronic myeloid leukemia in chronic phase from All India Institute of Medical Sciences, 1990-2010. Indian J Med Paediatr Oncol 2013;34:159-63.
- Doval DC, Batra U, Goyal S, Sharma A, Azam S, Shirali R. Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital. Indian J Med Paediatr Oncol 2013;34:182-5.
- Ganesan P, Rejiv R, Manjunath N, Sanju C, Sagar TG. Report of chronic myeloid leukemia in chronic phase from Cancer Institute (Women India Association), Chennai, 2002-2009. Indian J Med Paediatr Oncol 2013;34:206-7.
- Malhotra P, Varma N, Varma S. A short report on chronic myeloid leukemia from Post Graduate Institute of Medical Education and Research, Chandigarh. Indian J Med Paediatr Oncol 2013;34:186-8.
- Bansal S, Advani SH. Report of chronic myelogenous leukemia in chronic phase from, Asian Institute of Oncology, Mumbai, 2002-2010. Indian J Med Paediatr Oncol 2013;34:168-71.
- Dattatreya PS, Nirni SS. Report of chronic myeloid leukemia in chronic phase from Omega Hospital and Indo-American Centre, Hyderabad, 2004-2010. Indian J Med Paediatr Oncol 2013;34:204-5.
- Malhotra H, Sharma R, Singh Y, Chaturvedi H. Report of chronic myeloid leukemia SMS Medical College Hospital, Jaipur. Indian J Med Paediatr Oncol 2013;34:177-9.
- Maru A. Report of chronic myeloid leukemia from SEAROC experience, Jaipur over a period of 9 years. Indian J Med Paediatr Oncol 2013;34:180-1.
- Babu G. Report of patients with chronic myeloid leukemia Kidwai Memorial Institute of Oncology, Bangalore over 15 years. Indian J Med Paediatr Oncol 2013;34:196-8.
- Mukhopadhyay A, Dasgupta S, Mukhopadhyay S, Bose CK, Sarkar S, Gharami F, et al. Imatinib mesylate therapy in patients of chronic myeloid leukemia with Philadelphia chromosome positive: An experience from Eastern India. Indian J Hematol Blood Transfus 2012;28:82-8.
- Rajappa S, Mallavarapu KM, Gundeti S, Paul TR, Jacob RT, Digumarti R. Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate. Indian J Med Paediatr Oncol 2013;34:221-3.
- Ganesan P, Sagar TG, Dubashi B, Rajendranath R, Kannan K, Cyriac S, et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 2011;86:471-4.